Try our Advanced Search for more refined results

In Re: Prograf Antitrust Litigation

  1. February 04, 2016

    Astellas To Pay $13.3M To Settle Prograf Antitrust Case

    Astellas Pharma agreed Thursday to pay indirect purchasers of its Prograf $13.25 million to settle claims that it delayed generic competition to the immunosuppressant drug amid an appeal of class certification in the antitrust case.

  2. May 21, 2015

    Astellas Gets OK For $98M Deal In Prograf Antitrust MDL

    A Massachusetts federal judge on Wednesday signed off on a $98 million deal between buyers of organ transplant anti-rejection drug Prograf and Astellas Pharma US Inc., ending allegations Astellas delayed entry of a generic form of the immunosuppressant, while also approving a request from the buyers' lawyers for $34 million in fees and expenses.

  3. April 10, 2015

    Prograf Antitrust MDL Lawyers Seek $34M In Fees

    Attorneys for certain buyers of organ transplant anti-rejection drug Prograf sought $34 million in fees and expenses Thursday, three months after reaching a $98 million deal with Astellas Pharma US Inc. over allegations it delayed entry of a generic form of the immunosuppressant.

  4. March 06, 2015

    Pharm Co. Plans to Appeal Class Cert. In Antitrust MDL

    The First Circuit will hear Astellas Pharma US LLC's appeal of a judge's decision to partially certify a class of consumers and companies in multidistrict antitrust litigation accusing it of delaying entry of a generic form of its immunosuppressant Prograf, according to court filings.

  5. January 22, 2015

    Astellas Strikes $98M Deal In Prograf Antitrust MDL

    Astellas Pharma US LLC will pay $98 million to resolve some of the suits in multidistrict antitrust litigation accusing it of delaying entry of a generic form of its immunosuppressant Prograf, according to a Thursday filing in Massachusetts federal court.

  6. January 20, 2015

    Astellas Nears Settlement In Prograf Antitrust Row

    Astellas Pharma US LLC said on Tuesday that it had agreed in principle to a deal that would resolve some of the suits in multidistrict antitrust litigation accusing it of delaying entry of a generic form of its immunosuppressant Prograf, just as a trial was set to start in Massachusetts federal court.

  7. June 19, 2013

    Covington Fights Doc Request In Prograf Antitrust Row

    Covington & Burling LLP said Tuesday that certain evidence requested in Massachusetts federal court by a class of direct purchasers is not relevant to multidistrict antitrust litigation accusing Astellas Pharma US Inc. of delaying entry of a generic version of the immunosuppressant Prograf.

  8. June 04, 2013

    Purchasers Seek Covington Docs In Prograf Antitrust Row

    A direct purchaser class on Tuesday pushed a Massachusetts federal court to force Covington & Burling LLP to produce evidence that could be relevant to multidistrict antitrust litigation accusing Astellas Pharma US Inc. of delaying entry of a generic form of its immunosuppressant Prograf.

  9. April 24, 2013

    Pharma Cos. Get Cert. In MDL Over Generic Prograf Delays

    A Massachusetts federal judge on Tuesday certified a class of pharmaceutical companies in multidistrict antitrust litigation that accuses Astellas Pharma US Inc. of keeping a generic version of its immunosuppressant Prograf off the market, forcing the plaintiffs to pay higher prices for the drug. 

  10. February 01, 2012

    Astellas Can't Shake MDL Over Generic Prograf Delays

    A Massachusetts federal judge on Wednesday refused to dismiss multidistrict antitrust litigation accusing Astellas Pharma US Inc. of keeping a generic version of its immunosuppressant Prograf off the market and forcing direct purchasers to pay higher prices for the drug.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!